dulsevia 90 mg tvrdé gastrorezistentné kapsuly
krka, d.d., novo mesto, slovinsko - duloxetín - 30 - antidepressiva
sitagliptin krka 100 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin krka 50 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
maymetsi 50 mg/1000 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
maymetsi 50 mg/850 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagliptin/metformin krka 50 mg/850 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagavia met 50 mg/1000 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sitagavia met 50 mg/850 mg filmom obalené tablety
krka, d.d., novo mesto, slovinsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
sodium iodide (131i) injection
ge healthcare buchler gmbh & co. kg, nemecko - terapeutické rádiofarmaká - 88 - radiopharmaca